Franco Felizarta
Bakersfield College(US)
Publications by Year
Research Areas
HIV/AIDS drug development and treatment, Hepatitis C virus research, HIV Research and Treatment, Liver Disease Diagnosis and Treatment, HIV/AIDS Research and Interventions
Most-Cited Works
- → Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study(2013)509 cited
- → Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection(2018)430 cited
- → Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial(2017)339 cited
- → Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1–6 without cirrhosis(2017)296 cited
- → Brief Report(2015)216 cited
- → Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct‐acting antiviral treatment(2017)201 cited
- → Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)(2015)180 cited
- → Dolutegravir in antiretroviral-naive adults with HIV-1(2013)160 cited
- → Glecaprevir/pibrentasvir for 8 weeks in treatment-naïve patients with chronic HCV genotypes 1–6 and compensated cirrhosis: The EXPEDITION-8 trial(2019)151 cited
- → Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial(2017)145 cited